Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04723680
Other study ID # v3Nov2020
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 13, 2020
Est. completion date February 28, 2023

Study information

Verified date February 2023
Source Haemnet
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study programme aims to examine the real-world experience and impact of gene therapy in a diverse community of people and families affected by haemophilia who have been or will be exposed to gene therapy.


Description:

This is a prospective observational multiple cohort qualitative research study to be conducted among diverse groups within the haemophilia community whose lives may have been impacted by gene therapy. The study is designed to allow English-speaking patients and their families to tell their own life stories through narrative accounts. The narratives represent a true sharing of experiences and offer insight into how these patients and families cope with haemophilia.


Recruitment information / eligibility

Status Completed
Enrollment 69
Est. completion date February 28, 2023
Est. primary completion date February 28, 2023
Accepts healthy volunteers No
Gender Male
Age group 16 Years to 100 Years
Eligibility Inclusion Criteria: - People with haemophilia A or B who consented to and have undergone gene therapy in the early dose-finding studies and a member of their family - People with haemophilia A or B who consented to a gene therapy trial following the results of the early studies and a member of their family - People with haemophilia A or B who consented to a gene therapy trial but who withdrew, were withdrawn from, or were ineligible for the study, and a member of their family - People with haemophilia A or B who are definitely not interested in or unaware of gene therapy and a member of their family - People with haemophilia A or B who are interested in but have not been offered gene therapy - Those who have given written consent to be in the study - All participants will be =16 years. Exclusion Criteria: - Participants will be excluded if they do not speak English (for the interviews) or do not consent to be in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Qualitative interview
Qualitative semi structured interview

Locations

Country Name City State
United Kingdom Oxford University Hospitals NHS Foundation Trust Oxford Oxfordshire

Sponsors (2)

Lead Sponsor Collaborator
Haemnet UniQure Biopharma B.V.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary patient expectations To explore the expectations that patients, and families in the UK have of gene therapy and its position in contemporary and future haemophilia management Each participant & family member will take part in a 1 hour semi structured qualitative interview where his experiences of his condition, previous treatment & experience of gene therapy will be discussed & analysed using a grounded theory approach
Secondary Lived experience To understand the lived experience of people who have undergone gene therapy Each participant & family member will take part in a 1 hour semi structured qualitative interview where his experiences of his condition, previous treatment & experience of gene therapy will be discussed & analysed using a grounded theory approach
Secondary Impact of gene therapy To understand the as yet "unseen" impact of gene therapy on the extended family Each participant & family member will take part in a 1 hour semi structured qualitative interview where his experiences of his condition, previous treatment & experience of gene therapy will be discussed & analysed using a grounded theory approach
Secondary Impact of ineligibility To understand the impact of ineligibility for gene therapy trials Each participant & family member will take part in a 1 hour semi structured qualitative interview where his experiences of his condition, previous treatment & experience of gene therapy will be discussed & analysed using a grounded theory approach
Secondary Impact of withdrawal To understand the impact of withdrawal from gene therapy on individuals and their ongoing attitude to their haemophilia care Each participant & family member will take part in a 1 hour semi structured qualitative interview where his experiences of his condition, previous treatment & experience of gene therapy will be discussed & analysed using a grounded theory approach
Secondary Why not interested To understand why some patients and families opt not to participate in gene therapy trials as a treatment option Each participant & family member will take part in a 1 hour semi structured qualitative interview where his experiences of his condition, previous treatment & experience of gene therapy will be discussed & analysed using a grounded theory approach
See also
  Status Clinical Trial Phase
Recruiting NCT05617209 - In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
Completed NCT05039008 - Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy N/A
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Terminated NCT02586012 - Weight-based Dosing in Hemophilia A Phase 2
Completed NCT02546622 - ATHN 2: Factor Switching Study
Unknown status NCT02165592 - Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia N/A
Completed NCT02165462 - Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy N/A
Unknown status NCT02433782 - Myofascial Therapy in Patients With Hemophilic Arthropathy N/A
Completed NCT01232634 - Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles Phase 2
Completed NCT05104164 - Self-myofascial Release in Hemophilic Ankle Arthropathy N/A
Terminated NCT01191372 - First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients Phase 1
Completed NCT05173129 - Posture Analysis for Patients With Haemophilia N/A
Completed NCT03818529 - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Withdrawn NCT03996486 - Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia Phase 1
Completed NCT03842605 - Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia N/A
Completed NCT01708564 - A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B Phase 1
Completed NCT05549843 - Manual Therapy in the Treatment of Hemophilic Arthropathy of the Ankle N/A
Recruiting NCT06010953 - SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment Phase 1/Phase 2
Completed NCT05027230 - A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor Phase 1/Phase 2
Not yet recruiting NCT06014320 - Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease